ProShare Advisors’s Filana Therapeutics FLNA Stock Holding History

ProShare Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,438	Closed	-$27K	–	2224
2024 Q4	$27K	Buy	11,438 +3,764	+49%	+$66.1K	﹤0.01%	2243
2024 Q3	$226K	Buy	+7,674	New	+$177K	﹤0.01%	1658
2022 Q2	–	Sell	-7,176	Closed	-$267K	–	2076
2022 Q1	$267K	Sell	7,176 -1,224	-15%	-$51.9K	﹤0.01%	1710
2021 Q4	$366K	Buy	8,400 +3,501	+71%	+$184K	﹤0.01%	1669
2021 Q3	$304K	Sell	4,899 -5,027	-51%	-$420K	﹤0.01%	1542
2021 Q2	$848K	Buy	9,926 +1,181	+14%	+$63.3K	﹤0.01%	1129
2021 Q1	$393K	Buy	+8,745	New	+$344K	﹤0.01%	1616
2014 Q4	–	Sell	-2,160	Closed	-$59K	–	2098
2014 Q3	$59K	Sell	2,160 -488	-18%	-$14.8K	﹤0.01%	2243
2014 Q2	$107K	Buy	+2,648	New	+$98K	﹤0.01%	2341
2013 Q4	–	Sell	-2,280	Closed	-$43K	–	1770
2013 Q3	$43K	Sell	2,280 -2,486	-52%	-$43.5K	﹤0.01%	2510
2013 Q2	$74K	Buy	+4,766	New	+$101K	﹤0.01%	2315

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ProShare Advisors's FLNA Position: Q1 2025 in Review

ProShare Advisors sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 11,438 shares — an estimated $27K sold.

ProShare Advisors first reported a position in FLNA in Q2 2013 and held it in 11 quarters. The position peaked at $848K in Q2 2021. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

ProShare Advisors reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
ProShare Advisors sold 11,438 Filana Therapeutics shares in Q1 2025, an estimated $27K.
ProShare Advisors first reported a position in Filana Therapeutics in Q2 2013 and held it in 11 quarters.
ProShare Advisors's Filana Therapeutics position peaked at $848K in Q2 2021.
117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.